Acurx Pharmaceuticals LLC
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
- Ticker
- ACXP
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David P. Luci CPA, Esq., J.D.
- Headquarters
- 259 Liberty Avenue, Staten Island, NY, United States, 10305
- Employees
- 4
- Website
- acurxpharma.com
Metrics
Analyst Insights & forecasts
Based on information from 3 analysts.
Earnings per share (EPS) forecast
| Q3 • 25 | Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|---|
| Actual | -$1.23 | -$0.31 | -$0.62 | -$0.53 |
| Expected | -$1.48 | -$1.00 | -$0.63 | -$0.42 |
| Surprise | 16.89% | 68.84% | 1.59% | -26.19% |
| Beat | Beat | Beat | Current |
Financial Performance
| Q1 • 26 | Q2 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $0M | $0M | NaN% |
| Net income | $-1.7M | $-2.3M | 34.10% |
| Profit margin | -∞% | -∞% | NaN% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Acurx Pharmaceuticals LLC share?
Acurx Pharmaceuticals LLC shares are currently traded for undefined per share.
02How many shares does Acurx Pharmaceuticals LLC have?
Acurx Pharmaceuticals LLC currently has 5.5M shares.
03Does Acurx Pharmaceuticals LLC pay dividends?
No, Acurx Pharmaceuticals LLC doesn't pay dividends.
04What is Acurx Pharmaceuticals LLC 52 week high?
Acurx Pharmaceuticals LLC 52 week high is $7.54.
05What is Acurx Pharmaceuticals LLC 52 week low?
Acurx Pharmaceuticals LLC 52 week low is $0.95.
06What is the 200-day moving average of Acurx Pharmaceuticals LLC?
Acurx Pharmaceuticals LLC 200-day moving average is $1.94.
07Who is Acurx Pharmaceuticals LLC CEO?
The CEO of Acurx Pharmaceuticals LLC is David P. Luci CPA, Esq., J.D..
08How many employees Acurx Pharmaceuticals LLC has?
Acurx Pharmaceuticals LLC has 4 employees.
09What is the market cap of Acurx Pharmaceuticals LLC?
The market cap of Acurx Pharmaceuticals LLC is $5.8M.
10What is the P/E of Acurx Pharmaceuticals LLC?
The current P/E of Acurx Pharmaceuticals LLC is null.
11What is the EPS of Acurx Pharmaceuticals LLC?
The EPS of Acurx Pharmaceuticals LLC is -$2.67.
12What is the PEG Ratio of Acurx Pharmaceuticals LLC?
The PEG Ratio of Acurx Pharmaceuticals LLC is null.
13What do analysts say about Acurx Pharmaceuticals LLC?
According to the analysts Acurx Pharmaceuticals LLC is considered a buy.


